For the year ending 2025-12-31, NVAX has $1,176,512K in assets. $1,304,265K in debts. $240,634K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 240,634 | |||
| Marketable securities | 494,450 | |||
| Restricted cash | 10,876 | |||
| Accounts receivable | 106,446 | |||
| Inventory | 11,545 | |||
| Prepaid expenses and other current assets | 26,815 | |||
| Assets held for sale | 87,510 | |||
| Total current assets | 978,276 | |||
| Property and equipment, net | 44,800 | |||
| Right-of-use asset, net | 22,897 | |||
| Goodwill | 113,462 | |||
| Other non-current assets | 17,077 | |||
| Total assets | 1,176,512 | |||
| Accounts payable | 24,578 | |||
| Accrued expenses | 107,165 | |||
| Deferred revenue | 140,053 | |||
| Current portion of finance lease liabilities | 2,507 | |||
| Other current liabilities | 137,778 | |||
| Liabilities held for sale | 47,869 | |||
| Total current liabilities | 459,950 | |||
| Deferred revenue | 358,943 | |||
| Convertible notes payable | 244,213 | |||
| Non-current finance lease liabilities | 2,091 | |||
| Other non-current liabilities | 239,068 | |||
| Total liabilities | 1,304,265 | |||
| Common stock, 0.01 par value, 600,000,000 shares authorized at december31, 2025 and 2024 and 164,969,773 shares issued and 162,575,937 shares outstanding at december31, 2025 and 161,942,677 shares issued and 160,421,136 shares outstanding at december31, 2024 | 1,650 | |||
| Additional paid-in capital | 4,539,756 | |||
| Accumulated deficit | -4,568,148 | |||
| Treasury stock, 2,393,836 shares, cost basis at december31, 2025 and 1,521,541 shares, cost basis at december31, 2024 | 103,021 | |||
| Accumulated other comprehensive income (loss) | 2,010 | |||
| Total stockholders deficit | -127,753 | |||
| Total liabilities and stockholders deficit | 1,176,512 | |||
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)